Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00270907 · ClinicalTrials.gov registry record · Phase 1
CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00270907: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00270907 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00270907, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The safety and effectiveness of this combination will also be studied. This clinical trial will be offered to patients who are being considered for treatment with gemcitabine. Research lab samples and research biopsies will not be requested as part of this study.
Interventions
- DRUG Gemcitabine
- DRUG CT-2103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00270907
The ClinicalTrials.gov registry entry for NCT00270907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00270907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00270907 about?
NCT00270907 is a clinical study titled "CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer". The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The safety and effectiveness of this combination will also be studied. This clinical trial will be offered to patients w...
What is the current status of trial NCT00270907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2005-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00270907?
The interventions under investigation include: Gemcitabine (DRUG), CT-2103 (DRUG).
Who is sponsoring clinical trial NCT00270907?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.